Given that KRAS-mutant cervical cancer also shows reduced sensitivity to platinum/taxane-based chemotherapy, combining ferroptosis inducers with conventional chemotherapeutic agents offers a promising new approach to overcome this therapeutic resistance. The gene discussed is KRAS; the disease is cervical cancer.